Segment Reporting - Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment (Detail) - USD ($)
 3 Months Ended
Feb. 28, 2023
Feb. 28, 2022
Nov. 30, 2022
Segment Reporting Information [Line Items]      
Total net revenue $ 7,824,415 $ 7,258,531  
Total cost of sales 2,067,364 2,103,202  
Total operating profit 1,683,171 1,470,422  
Total depreciation and amortization 280,844 278,166  
Total interest expense 466,231 306,095  
Total assets 66,134,035   $ 64,888,054
Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Total depreciation and amortization 280,844 278,166  
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]      
Segment Reporting Information [Line Items]      
Total net revenue 7,561,518 7,157,486  
Total cost of sales 1,687,250 1,714,672  
Total operating profit 1,807,693 1,765,213  
Total assets 56,298,385   54,849,697
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Total depreciation and amortization 273,539 270,862  
Total interest expense 466,231 306,095  
PrepaCyte CB [Member]      
Segment Reporting Information [Line Items]      
Total net revenue 32,200 18,200  
Total cost of sales 17,122 30,658  
Total operating profit (8,133) (19,403)  
Total assets 140,439   176,546
PrepaCyte CB [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Total depreciation and amortization 6,945 6,944  
Public Cord Blood Banking [Member]      
Segment Reporting Information [Line Items]      
Total net revenue 230,697 82,845  
Total cost of sales 362,992 357,872  
Total operating profit (132,655) (275,388)  
Total assets 9,695,211   $ 9,861,811
Public Cord Blood Banking [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Total depreciation and amortization $ 360 $ 360